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Abstract 
Background: Whole‑exome sequencing (WES) has led to an exponential increase in identification of causative vari‑
ants in mitochondrial disorders (MD).
Methods: We performed WES in 113 MD suspected patients from Polish paediatric reference centre, in whom 
routine testing failed to identify a molecular defect. WES was performed using TruSeqExome enrichment, followed by 
variant prioritization, validation by Sanger sequencing, and segregation with the disease phenotype in the family.
Results: Likely causative mutations were identified in 67 (59.3 %) patients; these included variants in mtDNA (6 
patients) and nDNA: X‑linked (9 patients), autosomal dominant (5 patients), and autosomal recessive (47 patients, 
11 homozygotes). Novel variants accounted for 50.5 % (50/99) of all detected changes. In 47 patients, changes in 31 
MD‑related genes (ACAD9, ADCK3, AIFM1, CLPB, COX10, DLD, EARS2, FBXL4, MTATP6, MTFMT, MTND1, MTND3, MTND5, 
NAXE, NDUFS6, NDUFS7, NDUFV1, OPA1, PARS2, PC, PDHA1, POLG, RARS2, RRM2B, SCO2, SERAC1, SLC19A3, SLC25A12, TAZ, 
TMEM126B, VARS2) were identified. The ACAD9, CLPB, FBXL4, PDHA1 genes recurred more than twice suggesting higher 
general/ethnic prevalence. In 19 cases, variants in 18 non‑MD related genes (ADAR, CACNA1A, CDKL5, CLN3, CPS1, 
DMD, DYSF, GBE1, GFAP, HSD17B4, MECP2, MYBPC3, PEX5, PGAP2, PIGN, PRF1, SBDS, SCN2A) were found. The percentage 
of positive WES results rose gradually with increasing probability of MD according to the Mitochondrial Disease Cri‑
teria (MDC) scale (from 36 to 90 % for low and high probability, respectively). The percentage of detected MD‑related 
genes compared with non MD‑related genes also grew with the increasing MD likelihood (from 20 to 97 %). Molecu‑
lar diagnosis was established in 30/47 (63.8 %) neonates and in 17/28 (60.7 %) patients with basal ganglia involve‑
ment. Mutations in CLPB, SERAC1, TAZ genes were identified in neonates with 3‑methylglutaconic aciduria (3‑MGA) as 
a discriminative feature. New MD‑related candidate gene (NDUFB8) is under verification.
Conclusions: We suggest WES rather than targeted NGS as the method of choice in diagnostics of MD in chil‑
dren, including neonates with 3‑MGA aciduria, who died without determination of disease cause and with limited 
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Background
The diagnostics of mitochondrial disorders (MD) 
remains a challenge due to clinical heterogeneity [1] and 
the constantly expanding amount of gene candidates [2] 
as well as new phenotypes of these conditions [3]. There 
are eight published studies evaluating diagnostic utility 
of next generation sequencing (NGS) in mitochondrial 
patient cohorts, selected either based on particular bio-
chemical signatures of disease [4–8] or centre/cohort-
based studies [9–11]. However, of these only four used 
whole exome sequencing (WES) [7–10].
A particular challenge is the diagnosis of MD in neo-
nates below 3  months of age as these patients may 
account for up to 30 % of all MD cases [12, 13]. However, 
so far, this group has not been specifically focused on in 
terms of diagnostic effectiveness of WES. The prevail-
ing majority (96.5 %) of cases with a molecular diagnosis 
of MD established at our national reference centre until 
2013 included children older than 3  months, indicat-
ing considerable under-diagnosis rates in the youngest 
infants in the Polish population. We have achieved some 
improvement in neonatal MD detection by performing 
targeted DNA sequencing (frequently post mortem) in 
cases of neonates with lactic aciduria (LA-uria) found in 
selective GC–MS screening, including over 90 % of SCO2 
[14] and DGUOK [15] deficiencies, and ~ 50 % of SURF1 
deficiency [16].
The purpose of our study was to evaluate WES as a tool 
for diagnosis of MD depending on the disease probabil-
ity assessed according to mitochondrial disease criteria 
(MDC) [17]. We considered both patients with full-range 
mitochondrial diagnostics (Leigh syndrome features 
in MRI and/or muscle biopsy evaluation) and those in 
whom only fragmentary clinical data e.g. abnormal result 
of GC–MS screening indicating the presence LA-uria 




WES was performed in patients with probable or possible 
MD, in whom a molecular defect had not been identified 
within the analysed period. In the retrospective subgroup 
(88/113 patients) the lag time was 2–25 years (mean 7.5 
+/5.9  years). Since 2013 WES has been considered in 
consecutive patients (25/113). To undergo WES, a patient 
had to fulfil at least one of the following criteria: 1/neona-
tal onset; 2/basal ganglia involvement (Leigh syndrome—
LS, nonspecific basal ganglia involvement); 3/increased 
3-MGA in urine (patients recruited from a group of >250 
cases of 3-MGA aciduria identified by national selective 
GC–MS screening for metabolic disorders since 2000), 
and 4/genetic counselling demands. Access to biological 
material and informed consent of parents were sine qua 
non conditions for participation in the study. Details of 
criteria for patient selection and their clinical character-
istics are shown in Table 1 and Additional file 1: Table S1.
The study included cases with a high probability of MD 
and those in whom MD was considered possible. The 
level of probability was assessed according to the MDC 
score proposed by the Nijmegen mitochondrial team as 
follows: 2–4 points: MD possible; 5–8 points: MD prob-
able [17]. The MDC scoring for this study did not include 
the results of muscle biopsy (panels A+B, without C). 
The mean MD score in the study group was 4.1  ±  1.5 
(range 2–8). Muscle biopsy with subsequent OXPHOS 
evaluation was performed in 67 cases, and autopsy in 
15 cases. The family history was positive in 26 cases and 
three couples were consanguineous.
In the retrospective group, DNA was isolated from 
fibroblast cultures or frozen tissue samples obtained by 
muscle/liver biopsy or by autopsy. Whenever possible, 
skeletal muscle was preferred. In the remaining cases, 
DNA was isolated from blood. Throughout the paper the 
genes were classified as MD-related if they had a connec-
tion with mitochondrial disorders documented in the 
literature [9] or non MD-related when this was not the 
case.
Parents of the patients gave informed consent for the 
WES analysis. The study protocol was in agreement with 
the Helsinki Convention and the study was approved by 
the Ethics Committee of The Children’s Memorial Health 
Institute.
Whole‑exome sequencing
WES was performed using TruSeqExome Enrich-
ment Kits according to the manufacturer’s instructions 
(Illumina). The samples were run on 1/4 of a lane on 
HiSeq 1500 using 2 × 100 bp paired-end reads. Bioinfor-
matics analysis was performed as previously described 
[18]. Briefly, after initial processing with CASAVA, the 
sequencing reads were aligned to the hg19 reference 
availability of laboratory data. There is a strong correlation between the degree of MD diagnosis by WES and MD likeli‑
hood expressed by the MDC scale.
Keywords: Whole‑exome sequencing, Mitochondrial disorders, Mitochondrial disease criteria scale, Neonates, Basal 
ganglia involvement, Leigh syndrome, 3‑methylglutaconic aciduria, Novel mutation, Candidate gene
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Table 1 Characteristics of 113 MD suspected patients; inclusion criteria
ID  
patient















1 F 2009 + + 5 5
2 F 2013 + + 4 Autopsy 0
3 M 2012 + 5 + 2
4 F 2007 4 + 0
5 F 2013 + + + 5 0
6 F 2011 4 0
7 M 2006 + 5 + 7
8 M 2008 + 2 0
9 M 2011 + 6 + 2
10 M 2004 + 5 + 7
11 M 2005 2 2
12 M 2005 + 3 Autopsy 7
13 M 2014 + + + 4 Autopsy 0
14 F 2006 + 3 + Autopsy 7
15 F 2008 + + 4 + 5
16 M 2012 + 3 0
17 F 1992 + 3 + 21
18 F 2003 + 3 + 7
19 M 2009 5 + 3
20 M 2009 4 2
21 F 2006 + 6 + 8
22 M 2010 + + 8 + 2
23 M 2011 + + 4 + 3
24 F 2008 + 6 + 4
25 M 2010 + + 7 + 3
26 M 2011 + + 8 + 2
27 M 2008 + + + 5 6
28 M 2004 + + + 3 + 11
29 F 2007 + 5 + 7
30 F 2002 + + 2 + 13
31 F 2005 + 6 + 9
32 M 2002 + + 5 Autopsy 3
33 F 2006 3 2
34 M 2006 + 6 + 4
35 M 2012 + 6 + 2
36 M 2006 + + 5 + 6
37 M 2003 + + + 7 + 12
38 M 1985 3 + 12
39 M 1996 3 + 11
40 M 2010 + + + 5 Autopsy 4
41 F 2011 + 4 + 3
42 F 2013 2 0
43 M 1967 + 2 10
44 F 1956 4 3
45 F 1995 2 + 11
46 M 2009 3 + 4
47 M 2013 2 0
48 F 2007 2 4



















49 M 2012 + + 6 Autopsy 2
50 M 2009 + + 2 Autopsy 5
51 M 2003 + + + 5 + 12
52 F 2011 + 5 3
53 M 2007 6 + 7
54 M 1990 + 6 + 25
55 F 1981 4 + 21
56 F 2012 4 0
57 M 2010 + 6 + 0
58 M 2012 + 6 + 0
59 F 2010 + 6 + 4
60 M 2003 + + + 6 + 10
61 M 1989 + 8 + 23
62 M 1997 + + 6 + 18
63 F 1989 4 + 16
64 F 2012 + + 6 + 2
65 M 1991 + + 4 + 23
66 F 2012 + 5 + 2
67 F 2014 + + 4 0
68 M 2012 + 4 + 0
69 M 2013 3 0
70 F 2004 + 5 + 11
71 M 2001 + + 5 + 14
72 M 2011 + + 4 Autopsy 3
73 F 2002 + 3 + 11
74 F 1989 4 + 12
75 M 2008 + + 5 + 6
76 F 2003 + 4 + 6
77 F 2011 + + + 6 + 3
78 M 1994 + 3 17
79 M 2004 3 + 6
80 F 2012 + + 2 0
81 F 1990 + + 4 + Autopsy 21
82 F 2000 + 3 2
83 F 2003 + + 4 + 12
84 M 2010 + 3 + 4
85 F 2013 + + 3 0
86 M 2008 + 2 5
87 M 2010 3 0
88 M 1997 2 0
89 F 2004 + + + 4 + 11
90 M 2002 + 4 + 13
91 M 2009 + 6 + 5
92 M 1995 + 2 5
93 M 2011 + + 3 Autopsy 3
94 F 2010 + + 4 3
95 F 2011 + 4 + 3
96 M 2011 + 2 2
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genome with the Burrows-Wheeler Alignment Tool and 
further processed by Genome Analysis Toolkit [19]. Base 
quality score recalibration, indel realignment, duplicate 
removal, and SNP/INDEL calling were done as described 
[20]. The detected variants were annotated using Annovar 
and converted to MS Access format for final manual anal-
yses. Alignments were viewed with Integrative Genomics 
Viewer [21, 22]. The complete results of WES, includ-
ing VCF and/or FASTQ files, are available on demand to 
qualified researchers. All samples were sequenced so that 
min. 80 % of target was covered 20× or more.
The presence of the variants identified by WES was 
confirmed by Sanger sequencing.
Results
Among 67 probands, we found 99 variants in 49 different 
genes with a Known disease link (Table 2). They were var-
iants in mtDNA (6 patients) and nuclear DNA (nDNA): 
X-linked (9 patients), autosomal dominant (5 patients), 
and autosomal recessive (47 patients), including 11 
homozygotes. In 50.5  % (50/99) the detected variants 
were novel (Table 3). Sixty-six of the variants found in the 
study group occurred in MD-related genes, whereas 31 
were found in non MD-related loci. In addition, deleteri-
ous variants in a gene not previously linked to disease in 
humans were identified in one proband (Table 2).
Mutations in MD-related genes were found in 47 
probands. Identified pathogenic variants in 31 different 
genes included 27 located in nDNA and 4 in mtDNA 
(Table  2). Eleven genes were found defective more 
than once (PDHA1-4x, ACAD9, CLPB, and FBXL4-
3x, COX10, EARS2, MTND1, MTND5, PC, RRM2B, 
SLC19A3-2x). The majority of these genes were not pre-
viously screened for in our mitochondrial diagnostic cen-
tre, with the exceptions of TAZ, PDHA1 [23], SCO2, and 
the genes encoding MTND and MTATP subunits. Below 
we present the results that were analysed according to 
selected phenotypic features (neonatal onset, basal gan-
glia involvement, 3-MGA) and MD likelihood.
Subgroup of neonates
WES yielded conclusive results in 63.9 % (30/47) of neo-
nates studied (Fig. 1a). We found mutations in 23 differ-
ent genes, including 16 MD-related (ACAD9, AIFM1, 
CLPB, FBXL4, NDUFS6, NDUFS7, PARS2, PC, PDHA1 
[23], RRM2B, SERAC1, SLC19A3, SLC25A12, TAZ, 
TMEM126B, VARS2) and 7 non MD-related (CDKL5, 
CPS1, HSD17B4, MECP2, PGAP2, PRF1, SBDS). The 
majority of the neonates with positive WES results came 
from the first pregnancy of healthy unrelated parents. 
Twenty-nine neonates died before establishing a diagno-
sis; half in the early neonatal period. In 28 cases the mito-
chondrial testing was completed, including MR imaging 
and spectroscopy, muscle biopsy and fibroblast culture 
collection. In the remaining cases, mitochondrial diag-
nostics were absent or limited only to selective GC–MS 
screening showing increased excretion of lactate, Krebs 



















97 M 2005 + ND 4 + 10
98 F 2012 + + + 2 Autopsy 2
99 F 1974 2 0
100 M 2009 + 3 + 5
101 M 2012 + 4 0
102 F 2006 + 3 0
103 F 2008 + + + 3 Autopsy 4
104 F 1988 + 4 + 18
105 F 2014 + + 5 0
106 M 2011 + 3 + 2
107 M 2006 4 + 8
108 M 2012 + 3 + 2
109 M 1997 + + 4 Autopsy 18
110 M 2010 2 + 4
111 F 2014 + + 4 0
112 F 2010 + + 3 Autopsy 4
113 M 2013 + 4 + 0
F female, M male




























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Page 11 of 19Pronicka et al. J Transl Med  (2016) 14:174 




























Fig. 1 The percentage of detected MD‑related genes, non MD‑related genes and non‑conclusive WES results in (a) neonates (n = 47), b patients 
with 3‑MGA‑uria (n = 16) and c patients with basal ganglia involvement (n = 28)
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Subgroup with 3‑methylglutaonic aciduria
Positive WES results were obtained in seven of 16 
patients with persisting 3-MGA (Fig.  1b). In two sub-
jects [P28 and P37] we found mutations in TAZ and 
SERAC1 genes known to cause mitochondrial diseases 
with 3-MGA as a discriminative feature [24]. Ex post it 
was apparent that earlier some important clinical fea-
tures, including hearing impairment in the patient with 
SERAC1 mutations and increased excretion of 3-MGA in 
the terminal stage in the boy with the TAZ mutation, had 
been overlooked.
In three unrelated 3-MGA neonates included in this 
study, we identified mutations in the CLPB gene, whose 
link to human disease was subsequently established [25]. 
Two of them [P5 and P27] have already been reported in 
the first disease description [25].
Additionally, in two 3-MGA patients [P13, P40] we 
found molecular variants in the CPS1, a non MD-related 
gene linked to urea cycle disorder. In remaining patients 
in whom the reason for inclusion in the study group 
was a single GC–MS assessment (ACAD9 and MYBPC3 
patients [P15, P8]), increased excretion of 3-MGA has 
been apparently transient or it was within normal lim-
its after quantitative verification (Additional file 1: Table 
S1). Since traces of 3-MGA excretion were also found in 
a number of healthy siblings and parents of the patients 
the transient or mild increase in patients was most likely 
without a causal relationship.
Basal ganglia involvement (Leigh syndrome, Leigh‑like, 
others)
In 15 of 28 patients from this group (Fig. 1c), molecular 
variants in LS-associated genes, including genes respon-
sible for deficiency of complex I (MTND1, MTND3, 
MTND5, NDUFV1), complex IV (COX10), complex V 
(MTATP6), combined OXPHOS defect (EARS2, PARS2, 
RARS2, RRM2B, SERAC1, SLC19A3), and pyruvate dehy-
drogenase complex deficiency (DLD, PDHA1) [23] were 
identified. In the remaining 13 patients with LS or other 
basal ganglia involvement WES did not reveal variants in 
MD-related genes as listed by Neveling [9].
In three patients with basal ganglia involvement one 
MD-related candidate (NDUFB8) and two known non 
MD-related genes (ADAR, CDKL5) were identified.
Defects in non MD‑related genes
In 19 patients who were included in the study because of 
a possible (low probability) mitochondrial disease, muta-
tions in various non MD-related genes (ADAR, CAC-
NA1A, CDKL5, CLN3, CPS1, DMD, DYSF, GBE1, GFAP, 
HSD17B4, MECP2, MYBPC3, PEX5, PGAP2, PIGN, 
PRF1, SBDS, SCN2A) were identified (Table 2; Additional 
file 1: Table S1).
New MD‑related disorders
While our project was ongoing new candidate genes 
found by us including PARS2 [26] and CLPB have been 
described by other research teams [25]. The causal 
role of another two of our candidates has been recog-
nized even more recently. The NAXE gene (APOA1BP 
according to old nomenclature), a susceptibility locus 
for migraine [27], in which likely pathogenic vari-
ants were found by us in two brothers with a fatal 
encephalitis-like disorder [P12], has been described 
in April 2016 as the cause of lethal infantile leukoen-
cephalopathy in a large consanguineous family [28]. A 
homozygous variant in the TMEM126B gene encod-
ing a subunit required for mitochondrial complex I 
assembly [29, 30], found by us in a complex I deficient 
girl with extra-neurological presentation [P59], has 
been discovered and verified functionally as a cause of 
the disease in a subset of other patients (ESHG 2016, 
Alston et al.).
The interesting remaining candidate for a novel disease 
gene identified in our study is NDUFB8. Compound het-
erozygosity for two variants in NDUFB8 was found in a 
boy with a typical course of LS and complex I deficiency 
in muscle homogenate [P26] (Additional file 1: Table S1). 
NDUFB8 [31] encodes a known subunit of complex I, 
but, to the extent of our knowledge, its association with 
complex I deficiency and LS in humans has not been pub-
lished so far.
Mitochondrial disease criteria score
In the studied cohort there were 40 patients with high 
probability of MD, i.e., with an MDC score above 4 (5–8, 
criteria A+B, without C). Positive WES results were 
obtained in 36 of them (90 %). In this group, pathogenic 
variants were found mainly in MD-related genes (CPS1 
being the exception). WES failed in four patients [P49, 
P62, P77, P105] with an MDC score above 4. Some of 
them were found to carry a deleterious variant in one 
of the known MD-related genes only on one allele. The 
definite diagnosis still remains open in these cases. Bio-
informatics tools for identification of structural vari-
ants using NGS have not been applied to our data so it 
is possible that in some cases the disease may be caused 
by large deletions/duplications. The complete lists of 
variants detected in the subjects without fully conclusive 
results and/or the respective FASTQ files are available on 
demand to qualified researchers.
Intermediate probability of MD (MDC = 4) was associ-
ated with the occurrence of variants in both MD-related 
and non MD-related genes, in ten (10/31) and six (6/31) 
patients, respectively. MD-related genes were repre-
sented in this subset twice by ACAD9 [P15, P23] and 
PDHA1 [P56, P68], and in single cases by CLPB [P67], 
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FBLX4 [P55], POLG [P113], RARS2 [P41], SLC19A3 
[P109], and VARS2 [P97].
In the subgroup with low probability of MD, i.e., a 
MDC score of 2–3 points, positive WES results were 
obtained in 15 of 42 cases (36  %). Three MD-related 
genes (7 %) including: OPA1 [P33], TAZ [P28] and NAXE 
[P12] were found. Non MD-related genes were identified 
in 12 of 42 cases (29 %).
The percentage of positive results rose gradually as the 
likelihood of MD increased, as shown by the MDC score 
(Fig.  2). In the subset of high probability of MD (MDC 
above 4), the detection percentage reached 90  %. There 
was a broad range of MD-related genes (Table  2). Only 
one non MD-related gene (CPS1) was found in a neonate 
with a MDC score of 5.
The participation of detected MD-related genes as 
compared with non MD-related genes also grew as the 
likelihood of MD probability increased (from 20 to 97 %, 
data not shown).
WES diagnostics of current cases vs. archival DNA samples
Characteristics of the patients stratified by the waiting 
period between disease onset and WES qualification 
into archival material and current diagnostics subset is 
shown in Table 4. WES efficacy assessed as percentage of 
molecularly confirmed diagnoses was comparable being 
higher than 50 % in both subsets. Contribution of MD-
related genes expressed by the ratio of MD-related/non 
MD-related genes was higher in the archival than current 
subset (3.4 vs. 1.0, respectively) indicating that this subset 
contained more patients with non-mitochondrial genetic 
disorders and that our current qualification for WES 
became less demanding.
Muscle biopsy findings
OXPHOS assessment available for 67 muscle homoge-
nates showed isolated complex I deficiency in 16 cases, 
complex IV deficiency in 6 cases and combined OXPHOS 
defect in 10 cases. There were unspecific changes in 22 
bioptates and normal OXPHOS activity in 10. The results 
were not conclusive in three cases due to technical prob-
lems (too small muscle specimen, low protein concentra-
tion, low citric synthase activity).
Complex I deficiency was found in 11 patients with 
molecular variants in MD-related genes (ACAD9 [P15, 
P23, P53], NDUFV1 [P10], NDUFS7 [P75], MTND1 
[P64], MTND3 [P57], EARS2 [P7], SLC19A3 [P58], 
TMEM126B [P59]) and in one candidate (NDUFB8 
[P26]. In one patient [P95] a defect in non MD-related 
gene (SBDS) was found. In 4 patients WES results were 
not conclusive.
In the subset with complex IV deficiency molecu-
lar defects were confirmed in three patients including 
COX10 [P9, P36] and EARS2 [P70]) while three WES 
analyses were not conclusive.
Combined OXPHOS defect occurred in 8 patients 
with variants identified in MD-related genes (FBXL4 
[P3], ADCK3 [P61], RRM2B [P21, P51], AIFM1 [P25], 
TAZ [P28], PC [P71], MTND5 [P34]). In two cases WES 













Fig. 2 Efficacy of WES in 113 patients with possible or probable mitochondrial pathology depending on the level of probability expressed by MDC 
Nijmegen score
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Histological and histochemical data of the patients with 
positive WES showed presence of ragged red fibers in 
four cases (ADCK3 [P61], ACAD9 [P15, P23, P53]), “lipid 
storage myopathy” in four (PC [P71, P29], MTND5 [P35], 
PDHA1 [P66]) and SMA-like pattern in three (AIFM1 
[P25], SCO2 [P54], RRM2B [P51]).
Depletion of mitochondrial DNA (<30  % of reference 
value) was revealed in tissues of 8 patients. Molecular 
defect was established by WES in four of them (COX10 
[P9], FBXL4 [3], RRM2B [P21, P51]).
Verification of mitochondrial genome variants
Interestingly, in six patients with typical MD phenotype 
the search for pathogenic variants in MD-related nuclear 
genes by WES was negative yet pathogenic variants were 
found in mtDNA. Each mtDNA variant identified by 
WES, was subsequently verified by Sanger sequencing 
using specific primers for mitochondrial genome. All 
detected changes are known and have been repeatedly 
reported. Examination of different tissues in probands 
and maternally related family members showed varying 
levels of heteroplasmy (Fig. 3).
Discussion
Our results confirm that the implementation of WES led 
to a significant breakthrough in the diagnostics of MD 
in children [32]. This is expressed by both the increased 
number of identified genes and faster establishment of 
final diagnosis. The total number of genes with likely 
causative defects found in the present work was 47, a very 
satisfactory diagnostic yield when compared with 8 genes 
identified by us by single-gene Sanger sequencing before 
the introduction of WES (203 such diagnoses per ~1200 
patients studied in the period from 1996 to 2013).
In our study we observed a pronounced upward trend 
in the detection of the molecular background of mito-
chondrial diseases that was associated with increased 
MD probability (Fig.  2). According to the MDC scale 
that we used, a final genetic diagnosis was achieved in 
over 90 % of patients with the highest MDC scores (5–8 
points). In all such cases (with one exception for a neo-
nate with CPS1 mutation), variants were found exclu-
sively in MD-related genes. The diagnostic yield was 
the lowest (36 %) in the patients with low MD suspicion 
(MDC score 2–3), and most of the variants in this group 
were present in non MD-related genes.
Table 4 WES results related to the origin of the qualified material and to the specific inclusion criteria
a Italics in brackets indicates the number of patients in the given subset
LS Leigh syndrome, MD mitochondrial disorder, MD/non MD MD-related/non MD-related genes wherein variants were identified
Subgroups of patients MD or non‑MD genes  
loci of variants





Disease onset (year) 1996–2012 2013–2014 1996–2014
Number of patients 88 (5.5/year) 25 (12.5/year) 113
Period from onset to WES qualification (years) 2–25 (mean 5.5 ± 5.9 ) 0 0–25
MDC scale (A+B, without C) 4.2 ± 1.5 (2–8) 3.6 ± 1.2 (2–6) 4.1 ± 1.5
Ratio of MD‑related/non MD related genes 3.4 1.0 2.4
Patients deceased Total no. 41 8 44 %
MD 51.2 % (21) 2 47 % (23)
non MD (3) 2 (5)
Patients with neonatal onset Total no. 41 6 42 %
MD 53.7 % (22) 2 51 % (24)
non MD (5) 2 (7)
Patients with LS or other basal ganglia involvement Total no. 21 7 25 %
MD 61.9 % (13) 3 57 % (16)
non MD (2) 0 (2)
3‑methylglutaconic aciduria Total no. 13 3 14 %
MD 53.8 % (7) 2 53 % (9)
non MD 0 1 (1)
Muscle biopsy Total no. 62 5 67/113
MD 56.4 % (35) (4) 58 % (39)
non MD (10) (0) (10)
Percentage of muscle biopsy 70 % 20 % 59 %
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A similar correlation between detection rate and the 
level of MD probability was described recently in a simi-
lar patient group studied by WES at the Nijmegen Mito-
chondrial Centre [10]. However, our results differed from 
that study in terms of the scope of detected defects. In 
our cohort, mutations in MTO1, TK2, C12orf65, COA6, 
TUFM, GFM1 were absent and the defects in nuclear 
encoded complex I subunits are different. This may be 
a result of random patient selection, but we should also 
take into account ethnic differences among European 
populations, e.g., the Slavonic vs. north-western Euro-
pean populations.
In addition, we identified six rare mtDNA pathogenic 
variants, not included in the common mutations screen-
ing i.e. m.9185T>C in MTATP6 [33–35] and in mito-
chondrial DNA genes encoding complex I subunits, 
MTND1 [36–38], MTND3 and MTND5 [39–42].
One-third (15/47) of the identified gene defects were 
discovered during last 10  years and relatively poorly 
characterized in terms of phenotype. These included 
PGAP2 [43, 44], ACAD9 [45, 46], EARS2 [47], SERAC1 
[48], SLC19A3 [49, 50], MTFMT [51], SLC25A12 [52] as 
well as VARS2 [53], AIFM1 [54], RARS2 [55], RRM2B 
[56], PIGN [44, 57], ADCK3 [58, 59] which were 
described in just individual cases. Notably, most of these 
genes are generally absent from commercial NGS panels 
available at present.
It is worth emphasizing that in some cases WES 
allowed for a diagnosis in statu nascendi, that is, at the 
time of the first publication of the new gene. This con-
cerned, for example, mutations in CLPB [25, 60], PARS2 
[26], FBXL4 [61, 62] and recently added TMEM126B 
(data published on ESHG 2016 by Alston et  al.), and 
NAXE [28] In one of the patients with the MD phenotype 
we identified potentially pathogenic variants in candi-
date NDUFB8 which role in human pathology is under 











































male; female; affected individuals; death; m, muscle; u, urine; b, blood; s, saliva; f, fibroblasts; heteroplasmy level: +, low; ++,
moderate; +++, high, -, absent; PSEN1 molecular variant p.(Leu153Val) in P32 was a random WES finding, which revealed early Alzheimer disease
in the family: PSEN1+, detection , PSEN1-, absent
Fig. 3 Family study in six probands with mtDNA known mutations
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According to published literature, every third paediat-
ric MD case (approximately 30 % of all MD diagnoses in 
this age group) manifests clinically shortly after birth [12, 
13]. The fatal outcome in such cases precludes transport 
to a reference centre and proper mitochondrial diagnos-
tics. We have previously shown significantly reduced (up 
to ten times, about 3  % of all diagnoses) recognition of 
MD in this age group in Poland [16]. Therefore, neonates 
with suspected MD intentionally constituted a significant 
proportion of patients (47/113) undergoing WES in the 
present study.
Surprisingly, in the neonatal subgroup WES proved to 
be particularly useful, allowing identification of patho-
genic variants in 24 various genes in 63.8 % of patients, 
including those without muscle biopsy or even autopsy. 
Our results extend the list recommended by Honzik [13] 
for neonatal MD diagnostics by at least 15 genes (MD-
related: RRM2B, CLPB, ACAD9, FBXL4, PC, AIFM1, 
SLC25A12, MTND5, NDUFS6 and non MD-related: 
CPS1, PGAP2 and more).
In the LS subgroup WES expanded the set of patients 
from our centre diagnosed with complex I deficiency by 
three known genes: NDUFS6 [63, 64], NDUFV1 [65, 66], 
NDUFS7 [67], a new candidate NDUFB8 [68] and five 
MTNDs mentioned above. Despite this, complex I defi-
ciency continues to be underrepresented in our cohort 
in relation to complex IV deficiency because of the high 
carriage rate of SURF1 mutations in Poland [69]. In a 
number of cases with basal ganglia brain changes, WES 
failed to show mutations in known LS-associated genes. 
This was especially the case in patients without lactic aci-
daemia and MDC scores below 5 (MD possible but not 
likely). We speculate that other, still unknown, genes or 
non-genetic factors might influence the occurrence of 
LS-brain changes.
Taken together, our results indicate that WES rather 
than targeted NGS should be the method of choice for 
MD testing, at least until all MD-associated genes are 
identified. Furthermore, the rationale for choosing WES 
in MD-suspected neonates is the non-specificity of 
symptoms and overlapping results of biochemical tests 
with non-mitochondrial errors of metabolism.
In 50.5 % the molecular variants were novel (Table 3). 
However, a number of recurrent rare pathogenic variants 
found in some recently discovered MD genes (p.Arg22* in 
FBLX4, p.Arg518Cys in ACAD9, p.Arg417* in CLPB and 
c.1822_1828+10delinsACCAACAGG in SERAC1) may 
extend the ethnic specificity of MD in the Polish popu-
lation reported earlier by us for variants p.Glu140Lys in 
SCO2 [14] and c.845_846delCT in SURF1 genes [69]. 
Confirmation of these findings could facilitate in-house 
diagnostics in selected suspected cases.
Conclusions
1. In a nationwide reference centre, WES provided pos-
itive results in >90 % of children with high likelihood 
of MD (MDC score above 4);
2. WES should be recommended for diagnostics of 
mitochondrial pathology considering remarkable 
representation of non MD-related genes among 
causal factors in patients with lower likelihood of 
MD, as well as a possibility to discover new mito-
chondrial genes;
3. WES significantly improves recognition of MD in 
newborns, even in the case of limited availability of 
appropriate diagnostic procedures;
4. Despite being a sine qua non for certain diagnoses 
3-MGA is not a universal marker of mitochondrial 
dysfunction;
5. Recurrent variants recognized in some relatively new 
MD genes (FBLX4, ACAD9, and CLPB) may extend 
the known ethnic specificity of MD in the Polish 
population reported earlier for SCO2 and SURF1 var-
iants.
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